Independent Medical College, Faisalabad, Pakistan.
Faisalabad Medical University, Faisalabad, Pakistan.
Mult Scler Relat Disord. 2022 Sep;65:104002. doi: 10.1016/j.msard.2022.104002. Epub 2022 Jun 25.
Ublituximab is an anti-CD20 antibody that immunomodulates B-cells for relapsing multiple sclerosis (MS). With limited therapeutics available, this original meta-analysis seeks to determine the effect size (using RevMan 5.4.1) for annualized relapse rate (ARR), MRI outcomes and no evidence of disease activity (NEDA) by two years post-initiation of Ublituximab. Two RCTs (N = 1094) reveal Cohen's d for ARR= -0.17 (P = 0.006) favoring Ublituximab. MRI-tested, week 96 findings of T1 (Cohen's d= -0.43, P < 0.00001) and T2 (Cohen's d= -0.55; P < 0.00001) lesions favor Ublituximab compared to Teriflunomide. Less disease activity was reported in the Ublituximab group (OR=3.33, P < 0.00001). Further trials are required to corroborate findings.
乌利昔单抗是一种抗 CD20 抗体，可调节 B 细胞以治疗复发性多发性硬化症 (MS)。由于可供选择的治疗方法有限，本原始荟萃分析旨在确定乌利昔单抗起始后两年内的年化复发率 (ARR)、MRI 结果和无疾病活动证据 (NEDA) 的效应大小（使用 RevMan 5.4.1）。两项 RCT（N=1094）揭示 ARR 的 Cohen's d=-0.17（P=0.006），表明乌利昔单抗具有优势。在 MRI 测试中，第 96 周的 T1（Cohen's d=-0.43，P<0.00001）和 T2（Cohen's d=-0.55；P<0.00001）病变显示乌利昔单抗优于特立氟胺。乌利昔单抗组报告的疾病活动度较低（OR=3.33，P<0.00001）。需要进一步的试验来证实这些发现。
